Cognitive function and anticoagulation control in patients with atrial fibrillation

Circulation: Cardiovascular Quality and Outcomes

Volumn 3, Issue 3, 2010, Pages 277-283

  Flaker, Greg C ^a   Pogue, Janice ^b   Yusuf, Salim ^b   Pfeffer, Marc A ^c   Goldhaber, Samuel Z ^c   Granger, Christopher B ^d   Anand, Inderjit S ^e   Hart, Robert ^f   Connolly, Stuart J ^b  

^a UNIVERSITY OF MISSOURI   (United States)

^b MCMASTER UNIVERSITY   (Canada)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d DUKE UNIVERSITY   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

^f UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

Author keywords

Anticoagulants; Atrial fibrillation; Tachycardia

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTICOAGULANT AGENT; ANTIVITAMIN K; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; INSULIN; IRBESARTAN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; DEMENTIA; DISEASE ASSOCIATION; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; OUTCOME ASSESSMENT; PATIENT IDENTIFICATION; PREDICTION; PRIORITY JOURNAL; SCORING SYSTEM; VASCULAR DISEASE; ATRIAL FIBRILLATION; COMORBIDITY; DRUG INTERACTION; MIDDLE AGED; PSYCHOLOGY; QUESTIONNAIRE; RISK FACTOR; TREATMENT OUTCOME; UNITED STATES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AMIODARONE; ANTICOAGULANTS; ATRIAL FIBRILLATION; COMORBIDITY; DEMENTIA; DRUG INTERACTIONS; FEMALE; HUMANS; INSULIN; MALE; MIDDLE AGED; QUESTIONNAIRES; RISK FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 77953415235     PISSN: 19417713     EISSN: 19417705     Source Type: Journal    
DOI: 10.1161/CIRCOUTCOMES.109.884171     Document Type: Article

References (33)

1. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomized clinical trial. Lancet. 1996;348:633-638.
2. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825-1833.
3. Van Gelder C, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, Said SA, Darmanta JI, Timmermans AJM, Tijssen JGP, Crijns HJGM; for the Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347:1834-1840.
4. Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med. 1996;335:540-546.
5. Hart RG, Tonarelli SB, Pearce LA. Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas. Stroke. 2005;36:1588-1593.
6. The Stroke Prevention in Atrial Fibrillation Investigators. Bleeding during antithrombotic therapy in patients with atrial fibrillation. Arch Intern Med. 1996;156:409-416.
7. Mohr JP, Thompson JL, Lazar RM, Levin B, Sacco RL, Furie KL, Kistler JP, Albers GW, Pettigrew LC, Adams HP Jr, Jackson CM, Pullicino P. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med. 2001;345:1444-1451.
8. DiMarco JP, Flaker G, Waldo AL, Corley SD, Greene HL, Safford RE, Rosenfeld LE, Mitrani G, Nemeth M; The AFFIRM Investigators. Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J. 2005;149:650-656.
9. Cannegieter SC, Rosendall FR, Wintzen AR, Van Der Meer FJM, Vandenbroucke JP, Briet E. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med. 1995;333:11-17.
10. Vink R, Kraaijenhagen RA, Hutten BA, van den Brink RBA, de Mol BA, Büller HR, Levi M. The optimal intensity of vitamin K antagonists in patients with mechanical heart valves J Am Coll Cardiol. 2003;42:2042-2048.
11. Fang MC, Chang Y, Hylek EM, Rosand J, Greenberg SM, Go AS, Singer DE. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Int Med. 2004;141:745-752.
12. White HD, Gruber M, Feyzi J, Kaatz S, Tse H, Husted S, Albers GW. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control. Arch Intern Med. 2007;167:239-245.
13. Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P, Franzosi MG, Healey JS, Yusuf S. The benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of INR control achieved by centers and by countries as measured by time in therapeutic range. Circulation. 2008;118:2029-2037.
14. Wan Y, Heneghan C, Perara R, Roberts N, Hollowell J, Glasziou P, Bankhead C, Xu Y. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes. 2008;1:84-91.
15. SPORTIF Executive Steering Committee; for the SPORTIF V Investigators. Ximelagatran vs. warfarin for stroke prevention in patients with non-valvular atrial fibrillation: a randomized trial. J Am Med Assoc. 2005;93:690-698.
16. Executive Steering Committee; on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomized controlled trial. Lancet. 2003;362:1691-1698.
17. van Walraven C, Jennings A, Oake N, Fergusson D, Forster AJ. Effect of study setting on anticoagulation control. Chest. 2006;129:1155-66.
18. Folstein M, Folstein S, McHugh P. Mini-mental state: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
19. The ACTIVE. Writing Group; on behalf of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE W): a randomized controlled trial. Lancet. 2006;367:1903-1912.
20. 19a. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey J-Y, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). Circulation. 2006;114:700-752. (Pubitemid 44252312)
21. Rosendaal FR, Cannegieter SC, van der Meer FJM, Briet E. A method to determine the optimal intensity of anticoagulant therapy. Thromb Haemost. 1993;69:236-239
22. Braekhus A, Laake K, Engedal K. A low "normal" score on the Mini-Mental State Examination predicts development of dementia after three years J Am Geriatr Soc. 1995;43:656-661.
23. van Deelen BAJ, van den Bemt PMLA, Egberts TCG, van't Hoff A, Maas HAAM. Cognitive impairment as determinant for sub-optimal control of oral anticoagulation treatment in elderly patients with atrial fibrillation. Drugs Aging. 2005;22:353-260.
24. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV. Prevalence of diagnosed atrial fibrillation in adults. National implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors In Atrial Fibrillation (ATRIA) study. J Am Med Assoc. 2001;285:2370-2375.
25. Crum RM, Anthony JC, Bassett SS, Folstein MF. Population-based norms for the Mini-Mental State Examination by age and educational level. J Am Med Assoc. 1993;269:2386-2391.
26. Ott A, Breteler M, de Bruyne M, van Harskamp F, Grobbee D, Hofman A. Atrial fibrillation and dementia in a population-based study: the Rotterdam Study. Stroke. 1997;28:316-321. (Pubitemid 27096997)
27. Feinberg WM, Seeger JF, Carmody R, Anderson DC, Hart RG, Pearce LA. Epidemiologic features of asymptomatic cerebral infarction in patients with nonvalvular atrial fibrillation. Archives Int Med. 1990;150:2340-2344.
28. Petersen P, Madsen EB, Brun B, Pedersen F, Glydensted C, Boysen G. Silent cerebral infarction in chronic atrial fibrillation. Stroke. 1989;18:1098-1100.
29. Vernooij MW, Ikram MA, Tanghe HL, Vincent AJPE, Hofman A, Krestin GP, Niessen WJ, Breteler MMB, van der Lugt A. Incidental findings on brain MRI in the general population. N Engl J Med. 2007;357:1821-1828.
30. Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med. 2003;348:1215-2122.
31. Gagnon M, Letenneur L, Dartigues JF, Commenges D, Orgogozo JM, Barberger-Gateau P, Alpérovitch A, Décamps A, Salamon R. Validity of the Mini-Mental State Examination as a screening instrument for cognitive impairment and dementia in French elderly community residents. Neuroepidemiology. 1990;9:143-150.
32. Holtzer R, Verghese J, Wang C, Hall CB, Lipton RB. Within-person across-neuropsychological test variability and incident dementia. J Am Med Assoc. 2008;300:823-830.
33. Christensen H, Dear KB, Anstey KJ, Parslow RA, Sachdev P, Jorm AF. Within-occasion intraindividual variability and preclinical diagnostic status: is intraindividual variability an indicator of mild cognitive impairment? Neuropsychology. 2005;19:309-317.